Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer

References

• McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628. doi:10.1016/j.cell.2017.01.01828187284
   PubMed Web of Science ®Google Scholar
• Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–182. doi:10.1016/S0140-6736(18)32470-X30638582
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(6):595–606. doi:10.1001/jama.2017.2142129450530
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099–2106.12826431
   PubMed Web of Science ®Google Scholar
• Bast RC Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer. 2010;116(12):2850–2853. doi:10.1002/cncr.v116:1220564390
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Yasa C, Dural O, Bastu E, Ugurlucan FG, Nehir A, Iyibozkurt AC. Evaluation of the diagnostic role of transvaginal ultrasound measurements of endometrial thickness to detect endometrial malignancy in asymptomatic postmenopausal women. Arch Gynecol Obstet. 2016;294(2):311–316. doi:10.1007/s00404-016-4054-526946152
   PubMed Web of Science ®Google Scholar
• Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89(8):1765–1772. doi:10.1002/1097-0142(20001015)89:8<1765::AID-CNCR17>3.0.CO;2-F11042572
   PubMed Web of Science ®Google Scholar
• Lianidou E, Pantel K. Liquid biopsies. Genes Chromosomes Cancer. 2019;58(4):219–232. doi:10.1002/gcc.v58.430382599
   PubMed Web of Science ®Google Scholar
• Jia S, Zhang R, Li Z, Li J. Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. Oncotarget. 2017;8(33):55632–55645. doi:10.18632/oncotarget.v8i3328903450
   PubMedGoogle Scholar
• Cheng X, Zhang L, Chen Y, Qing C. Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer. J Ovarian Res. 2017;10(1):75. doi:10.1186/s13048-017-0369-529132396
   PubMedGoogle Scholar
• Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil. 1948;142(3–4):241–243.18875018
   PubMedGoogle Scholar
• Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–650.837366
   PubMed Web of Science ®Google Scholar
• Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994;86(4):774–779. doi:10.1111/j.1365-2141.1994.tb04828.x7918071
   PubMed Web of Science ®Google Scholar
• Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert Opin Biol Ther. 2012;12(Suppl 1):S209–S215. doi:10.1517/14712598.2012.68802322594497
   PubMedGoogle Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.11245480
   PubMed Web of Science ®Google Scholar
• Jiang P, Chan CW, Chan KC, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015;112(11):E1317–E1325. doi:10.1073/pnas.150007611225646427
   PubMed Web of Science ®Google Scholar
• Underhill HR, Kitzman JO, Hellwig S, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12(7):e1006162. doi:10.1371/journal.pgen.100616227428049
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra224. doi:10.1126/scitranslmed.3007094
   Web of Science ®Google Scholar
• Tug S, Helmig S, Deichmann ER, et al. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc Immunol Rev. 2015;21:164–173.25826002
   PubMed Web of Science ®Google Scholar
• Pandoh PK, Corbett RD, McDonald H, et al. A high-throughput protocol for isolating cell-free circulating tumor DNA from peripheral blood. Biotechniques. 2019;66(2):85–92. doi:10.2144/btn-2018-014830744412
   PubMed Web of Science ®Google Scholar
• Fettke H, Kwan EM, Azad AA. Cell-free DNA in cancer: current insights. Cell Oncol (Dordr). 2019;42(1):13–28. doi:10.1007/s13402-018-0413-530367445
   PubMed Web of Science ®Google Scholar
• Franczak C, Filhine-Tresarrieu P, Gilson P, Merlin JL, Au L, Harle A. Technical considerations for circulating tumor DNA detection in oncology. Expert Rev Mol Diagn. 2019;19(2):121–135. doi:10.1080/14737159.2019.156887330648442
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990. doi:10.1038/nm.178918670422
   PubMed Web of Science ®Google Scholar
• Medina Diaz I, Nocon A, Mehnert DH, Fredebohm J, Diehl F, Holtrup F. Performance of streck cfDNA blood collection tubes for liquid biopsy testing. PLoS One. 2016;11(11):e0166354. doi:10.1371/journal.pone.016635427832189
   PubMed Web of Science ®Google Scholar
• Lu JL, Liang ZY. Circulating free DNA in the era of precision oncology: pre- and post-analytical concerns. Chronic Dis Transl Med. 2016;2(4):223–230. doi:10.1016/j.cdtm.2016.12.00129063046
   PubMedGoogle Scholar
• Haselmann V, Ahmad-Nejad P, Geilenkeuser WJ, et al. Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). Clin Chem Lab Med. 2018;56(2):220–228. doi:10.1515/cclm-2017-028328841569
   PubMed Web of Science ®Google Scholar
• Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra168. doi:10.1126/scitranslmed.3003726
   Web of Science ®Google Scholar
• Buono G, Gerratana L, Bulfoni M, et al. Circulating tumor DNA analysis in breast cancer: is it ready for prime-time? Cancer Treat Rev. 2019;73:73–83. doi:10.1016/j.ctrv.2019.01.00430682661
   PubMed Web of Science ®Google Scholar
• Lise BA, Ostrup O. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA. APMIS. 2019;127:329–336.30784124
   PubMed Web of Science ®Google Scholar
• Butler TM, Johnson-Camacho K, Peto M, et al. Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease. PLoS One. 2015;10(8):e0136407. doi:10.1371/journal.pone.013640726317216
   PubMed Web of Science ®Google Scholar
• Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921. doi:10.1126/scitranslmed.aat492130404863
   PubMed Web of Science ®Google Scholar
• Shao X, He Y, Ji M, et al. Quantitative analysis of cell-free DNA in ovarian cancer. Oncol Lett. 2015;10(6):3478–3482. doi:10.3892/ol.2015.377126788153
   PubMed Web of Science ®Google Scholar
• Kamat AA, Baldwin M, Urbauer D, et al. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010;116(8):1918–1925. doi:10.1002/cncr.v116:820166213
   PubMed Web of Science ®Google Scholar
• Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Ann N Y Acad Sci. 2006;1075:230–234. doi:10.1196/annals.1368.03117108216
   PubMed Web of Science ®Google Scholar
• Zachariah RR, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol. 2008;112(4):843–850. doi:10.1097/AOG.0b013e3181867bc018827127
   PubMed Web of Science ®Google Scholar
• Dobrzycka B, Terlikowski SJ, Kinalski M, Kowalczuk O, Niklinska W, Chyczewski L. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers. Ann Oncol. 2011;22(5):1133–1140. doi:10.1093/annonc/mdq58421098618
   PubMed Web of Science ®Google Scholar
• Cicchillitti L, Corrado G, De Angeli M, et al. Circulating cell-free DNA content as blood based biomarker in endometrial cancer. Oncotarget. 2017;8(70):115230–115243. doi:10.18632/oncotarget.v8i7029383155
   PubMedGoogle Scholar
• Dobrzycka B, Terlikowski SJ, Mazurek A, et al. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer. 2010;127(3):612–621. doi:10.1002/ijc.v127:319960433
   PubMed Web of Science ®Google Scholar
• Vizza E, Corrado G, De Angeli M, et al. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. J Exp Clin Cancer Res. 2018;37(1):16. doi:10.1186/s13046-018-0688-429382392
   PubMedGoogle Scholar
• Tanaka H, Tsuda H, Nishimura S, et al. Role of circulating free alu DNA in endometrial cancer. Int J Gynecol Cancer. 2012;22(1):82–86. doi:10.1097/IGC.0b013e3182328c9422146763
   PubMed Web of Science ®Google Scholar
• Hickey KP, Boyle KP, Jepps HM, Andrew AC, Buxton EJ, Burns PA. Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients. Br J Cancer. 1999;80(11):1803–1808. doi:10.1038/sj.bjc.669060110468300
   PubMed Web of Science ®Google Scholar
• Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2(4):466–474. doi:10.1177/194760191140888921779514
   PubMedGoogle Scholar
• Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615. doi:10.1038/nature1016621720365
   PubMed Web of Science ®Google Scholar
• Otsuka J, Okuda T, Sekizawa A, et al. Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer. 2004;14(3):459–464. doi:10.1111/ijg.2004.14.issue-315228418
   PubMed Web of Science ®Google Scholar
• Park YR, Kim YM, Lee SW, et al. Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer. Obstet Gynecol Sci. 2018;61(3):328–336. doi:10.5468/ogs.2018.61.3.32829780774
   PubMedGoogle Scholar
• Swisher EM, Wollan M, Mahtani SM, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol. 2005;193(3 Pt 1):662–667. doi:10.1016/j.ajog.2005.01.05416150257
   PubMed Web of Science ®Google Scholar
• Cohen PA, Flowers N, Tong S, Hannan N, Pertile MD, Hui L. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening. BMC Med. 2016;14(1):126. doi:10.1186/s12916-016-0667-627558279
   PubMed Web of Science ®Google Scholar
• Vanderstichele A, Busschaert P, Smeets D, et al. Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses. Clin Cancer Res. 2017;23(9):2223–2231. doi:10.1158/1078-0432.CCR-16-107827852697
   PubMed Web of Science ®Google Scholar
• Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403). doi:10.1126/scitranslmed.aan2415
   PubMed Web of Science ®Google Scholar
• Farkkila A, McConechy MK, Yang W, et al. FOXL2 402C>G mutation can be identified in the circulating tumor DNA of patients with adult-type granulosa cell tumor. J Mol Diagn. 2017;19(1):126–136. doi:10.1016/j.jmoldx.2016.08.00527810330
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang L, Ho SS, Wu X, Gu J. Lower mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of endometrial cancer. Mol Carcinog. 2016;55(6):1111–1117. doi:10.1002/mc.v55.626258624
   PubMed Web of Science ®Google Scholar
• Clay Montier LL, Deng JJ, Bai Y. Number matters: control of mammalian mitochondrial DNA copy number. J Genet Genomics. 2009;36(3):125–131. doi:10.1016/S1673-8527(08)60099-519302968
   PubMed Web of Science ®Google Scholar
• Li L, Li C, Mao H, et al. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci Rep. 2016;6:26591. doi:10.1038/srep2659127225590
   PubMed Web of Science ®Google Scholar
• Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou ES. RASSF1A promoter methylation in high-grade serous ovarian cancer: a direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Oncotarget. 2017;8(13):21429–21443. doi:10.18632/oncotarget.v8i1328206954
   PubMed Web of Science ®Google Scholar
• Zhang Q, Hu G, Yang Q, et al. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol. 2013;130(1):132–139. doi:10.1016/j.ygyno.2013.04.04823623832
   PubMed Web of Science ®Google Scholar
• Liggett TE, Melnikov A, Yi Q, et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011;120(1):113–120. doi:10.1016/j.ygyno.2010.09.01921056906
   PubMed Web of Science ®Google Scholar
• Melnikov A, Scholtens D, Godwin A, Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn. 2009;11(1):60–65. doi:10.2353/jmoldx.2009.08007219074590
   PubMed Web of Science ®Google Scholar
• Widschwendter M, Zikan M, Wahl B, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med. 2017;9(1):116. doi:10.1186/s13073-017-0500-729268796
   PubMedGoogle Scholar
• Li L, Zheng H, Huang Y, et al. DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. Carcinogenesis. 2017;38(8):797–805. doi:10.1093/carcin/bgx05728637314
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang X, Lin L, Ma XP, Ma YC, Liu PS. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. Asian Pac J Cancer Prev. 2014;15(3):1171–1176. doi:10.7314/APJCP.2014.15.3.117124606436
   PubMedGoogle Scholar
• Ibanez de Caceres I, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004;64(18):6476–6481. doi:10.1158/0008-5472.CAN-04-152915374957
   PubMed Web of Science ®Google Scholar
• Iwasa H, Hossain S, Hata Y. Tumor suppressor C-RASSF proteins. Cell Mol Life Sci. 2018;75(10):1773–1787. doi:10.1007/s00018-018-2756-529353317
   PubMed Web of Science ®Google Scholar
• Fernandes MS, Carneiro F, Oliveira C, Seruca R. Colorectal cancer and RASSF family – a special emphasis on RASSF1A. Int J Cancer. 2013;132(2):251–258. doi:10.1002/ijc.2769622733432
   PubMed Web of Science ®Google Scholar
• Schmidt ML, Hobbing KR, Donninger H, Clark GJ. RASSF1A deficiency enhances RAS-driven lung tumorigenesis. Cancer Res. 2018;78(10):2614–2623. doi:10.1158/0008-5472.CAN-17-246629735543
   PubMed Web of Science ®Google Scholar
• Margolin G, Petrykowska HM, Jameel N, Bell DW, Young AC, Elnitski L. Robust detection of DNA hypermethylation of ZNF154 as a pan-cancer locus with in silico modeling for blood-based diagnostic development. J Mol Diagn. 2016;18(2):283–298. doi:10.1016/j.jmoldx.2015.11.00426857064
   PubMed Web of Science ®Google Scholar
• Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13(12):e1002198. doi:10.1371/journal.pmed.100219827997533
   PubMed Web of Science ®Google Scholar
• Kamat AA, Bischoff FZ, Dang D, et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther. 2006;5(10):1369–1374. doi:10.4161/cbt.5.10.324016969071
   PubMed Web of Science ®Google Scholar
• Bolivar AM, Luthra R, Mehrotra M, et al. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients. Modern Pathol. 2019;32(3):405–414. doi:10.1038/s41379-018-0158-8
   PubMed Web of Science ®Google Scholar
• Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. Int J Cancer. 2011;128(11):2572–2580. doi:10.1002/ijc.v128.1120715113
   PubMed Web of Science ®Google Scholar
• Perkins G, Yap TA, Pope L, et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One. 2012;7(11):e47020. doi:10.1371/journal.pone.004702023144797
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Madsen CV, Andersen RF, Waldstrom M, Adimi P, Jakobsen A. Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. Eur J Cancer. 2014;50(15):2611–2618. doi:10.1016/j.ejca.2014.06.02225087181
   PubMed Web of Science ®Google Scholar
• No JH, Kim K, Park KH, Kim YB. Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. Anticancer Res. 2012;32(8):3467–3471.22843932
   PubMed Web of Science ®Google Scholar
• Kuhlmann JD, Schwarzenbach H, Wimberger P, Poetsch M, Kimmig R, Kasimir-Bauer S. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. BMC Cancer. 2012;12:325. doi:10.1186/1471-2407-12-32522849543
   PubMed Web of Science ®Google Scholar
• Giannopoulou L, Mastoraki S, Buderath P, et al. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. Gynecol Oncol. 2018;150(2):355–360. doi:10.1016/j.ygyno.2018.05.02629807696
   PubMed Web of Science ®Google Scholar
• Harris FR, Kovtun IV, Smadbeck J, et al. Quantification of somatic chromosomal rearrangements in circulating cell-free DNA from ovarian cancers. Sci Rep. 2016;6:29831. doi:10.1038/srep2983127436510
   PubMed Web of Science ®Google Scholar
• Pereira E, Camacho-Vanegas O, Anand S, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. PLoS One. 2015;10(12):e0145754. doi:10.1371/journal.pone.014575426717006
   PubMed Web of Science ®Google Scholar
• Du ZH, Bi FF, Wang L, Yang Q. Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer. Mol Genet Genomic Med. 2018. doi:10.1002/mgg3.414
   Web of Science ®Google Scholar
• Martignetti JA, Camacho-Vanegas O, Priedigkeit N, et al. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. Neoplasia. 2014;16(1):97–103. doi:10.1593/neo.13190024563622
   PubMed Web of Science ®Google Scholar
• Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment. Int J Mol Sci. 2016;17(12):2113. doi:10.3390/ijms17122113
   PubMed Web of Science ®Google Scholar
• Choudhuri S, Sharma C, Banerjee A, Kumar S, Kumar L, Singh N. A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer. Mol Cell Biochem. 2014;386(1–2):259–269. doi:10.1007/s11010-013-1863-824141793
   PubMed Web of Science ®Google Scholar
• Capizzi E, Gabusi E, Grigioni AD, et al. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer. Diagn Mol Pathol. 2008;17(1):34–38. doi:10.1097/PDM.0b013e3181359e1f18303408
   PubMedGoogle Scholar
• Arend RC, Londono AI, Montgomery AM, et al. Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma. Mol Cancer Res. 2018;16(5):813–824. doi:10.1158/1541-7786.MCR-17-059429523763
   PubMed Web of Science ®Google Scholar
• Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004;10(13):4420–4426. doi:10.1158/1078-0432.CCR-03-073215240532
   PubMed Web of Science ®Google Scholar
• Flanagan JM, Wilson A, Koo C, et al. Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in patients with ovarian cancer. Clin Cancer Res. 2017;23(9):2213–2222. doi:10.1158/1078-0432.CCR-16-175427663594
   PubMed Web of Science ®Google Scholar
• Weigelt B, Comino-Mendez I, de Bruijn I, et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin Cancer Res. 2017;23(21):6708–6720. doi:10.1158/1078-0432.CCR-17-054428765325
   PubMed Web of Science ®Google Scholar
• Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol. 2017;35(12):1274–1280. doi:10.1200/JCO.2016.70.462728414925
   PubMed Web of Science ®Google Scholar
• Lin KK, Harrell MI, Oza AM, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9(2):210–219. doi:10.1158/2159-8290.CD-18-071530425037
   PubMed Web of Science ®Google Scholar
• Matulonis U, Vergote I, Backes F, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015;136(2):246–253. doi:10.1016/j.ygyno.2014.12.01925528496
   PubMed Web of Science ®Google Scholar
• La Rosa VL, Shah M, Kahramanoglu I, et al. Quality of life and fertility preservation counseling for women with gynecological cancer: an integrated psychological and clinical perspective. J Psychosom Obstet Gynaecol. 2019;1–7. doi:10.1080/0167482X.2019.1648424
   Web of Science ®Google Scholar
• Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–591. doi:10.1038/nrc140815286738
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24–vi32. doi:10.1093/annonc/mdt33324078660
   PubMed Web of Science ®Google Scholar
• Vitale SG, Rossetti D, Tropea A, Biondi A, Lagana AS. Fertility sparing surgery for stage IA type I and G2 endometrial cancer in reproductive-aged patients: evidence-based approach and future perspectives. Updates Surg. 2017;69(1):29–34. doi:10.1007/s13304-017-0419-y28188573
   PubMed Web of Science ®Google Scholar
• Cignini P, Vitale SG, Lagana AS, Biondi A, La Rosa VL, Cutillo G. Preoperative work-up for definition of lymph node risk involvement in early stage endometrial cancer: 5-year follow-up. Updates Surg. 2017;69(1):75–82. doi:10.1007/s13304-017-0418-z28108938
   PubMed Web of Science ®Google Scholar
• Ortoft G, Dueholm M, Mathiesen O, et al. Preoperative staging of endometrial cancer using TVS, MRI, and hysteroscopy. Acta Obstet Gynecol Scand. 2013;92(5):536–545. doi:10.1111/aogs.2013.92.issue-523398280
   PubMed Web of Science ®Google Scholar
• Pronin SM, Novikova OV, Andreeva JY, Novikova EG. Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer. 2015;25(6):1010–1014. doi:10.1097/IGC.000000000000046725950126
   PubMed Web of Science ®Google Scholar
• Pal N, Broaddus RR, Urbauer DL, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 2018;131(1):109–116. doi:10.1097/AOG.000000000000239029215513
   PubMed Web of Science ®Google Scholar
• Janda M, McGrath S, Obermair A. Challenges and controversies in the conservative management of uterine and ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2019;55:93–108. doi:10.1016/j.bpobgyn.2018.08.00430243603
   PubMed Web of Science ®Google Scholar
• Greenwald ZR, Huang LN, Wissing MD, Franco EL, Gotlieb WH. Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer? Cancer. 2017;123(9):1545–1554. doi:10.1002/cncr.v123.928026855
   PubMed Web of Science ®Google Scholar
• Schuurman MS, Kruitwagen R, Portielje JEA, Roes EM, Lemmens V, van der Aa MA. Treatment and outcome of elderly patients with advanced stage ovarian cancer: a nationwide analysis. Gynecol Oncol. 2018;149(2):270–274. doi:10.1016/j.ygyno.2018.02.01729514738
   PubMed Web of Science ®Google Scholar
• Vitale SG, Capriglione S, Zito G, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Arch Gynecol Obstet. 2019;299(2):299–315. doi:10.1007/s00404-018-5006-z30542793
   PubMed Web of Science ®Google Scholar
• Ponti G, Manfredini M, Tomasi A. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Crit Rev Oncol Hematol. 2019;141:36–42. doi:10.1016/j.critrevonc.2019.06.00531212145
   PubMed Web of Science ®Google Scholar
• Krimmel JD, Schmitt MW, Harrell MI, et al. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci U S A. 2016;113(21):6005–6010. doi:10.1073/pnas.160131111327152024
   PubMed Web of Science ®Google Scholar
• Parrella P, Zangen R, Sidransky D, Nicol T. Molecular analysis of peritoneal fluid in ovarian cancer patients. Modern Pathol. 2003;16(7):636–640. doi:10.1097/01.MP.0000076979.28106.ED
   PubMed Web of Science ®Google Scholar
• Barquin M, Maximiano C, Perez-Barrios C, et al. Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies. Pathol Res Pract. 2019;215(2):392–394. doi:10.1016/j.prp.2018.10.02830392916
   PubMed Web of Science ®Google Scholar
• Muller HM, Millinger S, Fiegl H, et al. Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem. 2004;50(11):2171–2173.15502091
   PubMed Web of Science ®Google Scholar
• Nair N, Camacho-Vanegas O, Rykunov D, et al. Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer: a prospective cross-sectional study. PLoS Med. 2016;13(12):e1002206. doi:10.1371/journal.pmed.100220628027320
   PubMed Web of Science ®Google Scholar
• Maritschnegg E, Wang Y, Pecha N, et al. Lavage of the uterine cavity for molecular detection of mullerian duct carcinomas: a proof-of-concept study. J Clin Oncol. 2015;33(36):4293–4300. doi:10.1200/JCO.2015.61.308326552420
   PubMed Web of Science ®Google Scholar
• Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5(167):167ra164. doi:10.1126/scitranslmed.3004952
   Web of Science ®Google Scholar
• Wang Y, Li L, Douville C, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 2018;10(433). doi:10.1126/scitranslmed.aap8793
   Web of Science ®Google Scholar
• Kwapisz D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med. 2017;5(3):46. doi:10.21037/atm28251125
   PubMed Web of Science ®Google Scholar